SR&ED for the Life Sciences and Pharmaceuticals Industry: R&D Tax Credits and Incentives
Can Your Life Sciences and Pharmaceutical Projects Qualify for SR&ED?
Canada's life sciences and pharmaceutical industry continues to advance through developments in drug discovery, pharmaceutical formulations, biopharmaceutical manufacturing, drug delivery technologies, chemical synthesis and innovative therapeutic products. Pharmaceutical companies, drug developers, contract research organizations, contract development and manufacturing organizations, and life sciences businesses regularly encounter complex scientific and technological challenges as they work to improve drug stability, therapeutic performance, manufacturing efficiency, product quality and production scalability.
Canada's Scientific Research and Experimental Development (SR&ED) tax incentive program provides tax incentives for eligible research and development activities undertaken to achieve scientific or technological advancements. Life sciences and pharmaceutical businesses developing new drug formulations, experimenting with pharmaceutical manufacturing processes or investigating unresolved challenges involving chemical compounds, biological products or drug delivery technologies may qualify for SR&ED tax credits when their work meets the program's eligibility requirements.
What Type of Activities and Technological Challenges May Qualify?
Drug discovery and pharmaceutical development:
Investigating new pharmaceutical compounds, molecular structures or therapeutic substances to overcome scientific uncertainties involving chemical properties, molecular interactions, biological activity, compound stability or mechanisms of action.
Pharmaceutical formulation development:
Experimenting with new drug formulations, excipient combinations or pharmaceutical compositions to address unresolved challenges involving solubility, bioavailability, chemical stability, dissolution rates, compatibility or controlled drug release.
Drug delivery and release technologies:
Developing or modifying pharmaceutical delivery methods, encapsulation techniques or controlled-release formulations to overcome technological challenges involving drug absorption, release profiles, compound degradation or delivery efficiency.
Biopharmaceutical and biologic drug development:
Investigating new methods for developing, producing or stabilizing biologic pharmaceuticals, including proteins, antibodies and other biological therapeutics, to address scientific uncertainties involving molecular stability, biological activity, aggregation or product consistency.
Pharmaceutical manufacturing and process optimization:
Experimenting with new pharmaceutical production methods, reaction conditions, purification processes or manufacturing techniques to overcome technical limitations involving product yield, process consistency, impurity formation, batch variability or production scalability.
Chemical synthesis and active pharmaceutical ingredients (APIs):
Developing or modifying chemical synthesis routes, catalytic processes or purification methods to address unresolved challenges involving reaction efficiency, molecular selectivity, chemical impurities, compound purity or manufacturing reproducibility.
Fermentation and bioprocess development:
Investigating new fermentation methods, cell culture conditions or bioreactor processes to overcome technological uncertainties involving biological productivity, process stability, product yield, contamination control or large-scale pharmaceutical production.
Pharmaceutical stability and degradation research:
Conducting systematic investigations into drug degradation, molecular interactions, environmental sensitivity or formulation stability to develop new methods for maintaining pharmaceutical quality, potency and performance.
Advanced pharmaceutical analytical methods:
Developing new analytical techniques or testing methodologies to overcome scientific or technological limitations involving the identification, characterization or quantification of pharmaceutical compounds, impurities, degradation products or complex biological substances.
Pharmaceutical scale-up and technology transfer:
Experimenting with new production parameters, manufacturing configurations or process control methods to overcome technological uncertainties encountered when transitioning pharmaceutical products from laboratory development to pilot-scale or commercial manufacturing.
The key question is whether your business is working to overcome a scientific or technological challenge that could not be readily resolved using existing knowledge or standard industry practices.
What Life Sciences and Pharmaceutical Costs May Qualify for SR&ED?
Once a project has been identified as potentially eligible for SR&ED, the next step is determining which expenditures are associated with the eligible R&D work. Depending on the nature of the project, potentially qualifying expenditures can include employee labour, materials, contractors and certain lease or capital expenditures.
Labour
Materials
Contractors and Specialized Services
Lease and Capital Expenditures
Recent changes to the SR&ED program have made certain qualifying capital expenditures incurred after December 15, 2024, eligible for SR&ED.
If your project involves these types of activities and costs, it may be worth assessing whether the work and associated expenditures qualify for SR&ED.
Not every pharmaceutical development project, laboratory investigation, formulation modification or manufacturing improvement qualifies for SR&ED. Eligible work must involve scientific or technological uncertainty, a systematic investigation or search through experiment or analysis, and an attempt to achieve scientific or technological advancement. Routine quality control, standard formulation adjustments, established manufacturing procedures, regulatory compliance activities and conventional pharmaceutical testing do not automatically qualify.
Other Funding Opportunities for Life Sciences and Pharmaceutical Businesses
Depending on the project, company, location and activities involved, additional funding may be available through federal, provincial and regional programs.
Potential sources may include:
NRC IRAP (Industrial Research Assistance Program)
Provides expert advisory services and potential financial support to eligible Canadian small and medium-sized businesses developing innovative technologies, products and processes. Life sciences and pharmaceutical businesses may benefit from support for pharmaceutical formulation development, drug delivery technologies, biopharmaceutical production processes, innovative chemical synthesis methods and other technology-driven R&D projects.
Strategic Innovation Fund (SIF)
Provides potential support for eligible large-scale innovation, industrial transformation and strategic business investment projects. Life sciences and pharmaceutical companies undertaking significant investments in pharmaceutical manufacturing, biomanufacturing capacity, innovative production technologies or strategic domestic pharmaceutical capabilities may qualify under applicable funding opportunities.
Mitacs Accelerate
Supports collaborative research internships connecting businesses with academic researchers to address scientific and technological challenges. Potential applications within the life sciences and pharmaceutical industry include drug formulation research, medicinal chemistry, pharmaceutical process development, biopharmaceutical production, chemical synthesis and advanced analytical research.
NGen (Next Generation Manufacturing Canada)
Supports collaborative advanced manufacturing projects involving innovative production technologies, automation, digital manufacturing and advanced industrial processes. Pharmaceutical and life sciences manufacturers may benefit from opportunities supporting advanced pharmaceutical production systems, automated manufacturing technologies, bioprocess optimization, digital process monitoring and innovative manufacturing methods.
Innovative Solutions Canada (ISC)
Provides opportunities for eligible Canadian innovators to develop and demonstrate solutions to challenges identified by participating federal government departments and agencies. Life sciences and pharmaceutical businesses developing innovative technologies may be able to participate in relevant funding opportunities where their proposed solutions align with an active government challenge.
Additional federal, provincial and regional programs may also be available depending on the company's location and project objectives.
Government funding programs change frequently. Eligibility, application windows and available funding should be reviewed based on the specific project and timing.
Funding programs can have specific eligibility requirements, application periods and eligible-cost rules. In some cases, SR&ED and government funding may interact, so businesses should consider their available incentives when planning and documenting a project.
How EVAMAX Can Help
Navigating Canada's tax incentives and grants can be complex. Life sciences and pharmaceutical projects often involve multiple stages of research, experimental development, process optimization, manufacturing scale-up and commercialization, each of which may have different eligibility requirements and funding opportunities.
EVAMAX helps life sciences and pharmaceutical businesses identify and pursue opportunities across SR&ED, tax incentives, grants and government funding programs.